ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Scientific and diagnostic instrument maker PerkinElmer has agreed to acquire Caliper Life Sciences, a molecular and tissue imaging expert, for $600 million. The $10.50-per-share purchase price represents a 42% premium over Caliper’s closing stock price on Sept. 7. Pending government reviews, the deal is expected to be completed by the end of the year. Perkin CEO Robert F. Friel says the acquisition brings “innovative molecular imaging and detection technologies to our portfolio.” Those capabilities, along with Caliper’s DNA sequencing, sample preparation, and microfluidics technologies, will complement Perkin’s offerings in life sciences, diagnostic, environmental, and food markets. In a report to clients, analyst Peter Lawson of Mizuho Securities USA calls the deal “synergistic” and says it removes concern that Perkin might pursue a deal outside its core markets.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X